Regeneron pharmaceuticals (regn) faces securities class action after losing $9 billion value following q3 2024 earnings report– hagens berman

San francisco, jan. 10, 2025 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) faces a securities fraud class action after shares of the company plunged $84.59 on oct. 31, 2024, wiping out about $9 billion of market value. hagens berman has opened an investigation into whether regeneron may have misled investors about its marketing and reimbursement practices related to its eylea product, an injection to treat age-related macular degeneration by inhibiting anti vascular endothelial growth factor (“anti-vegf”), and urges investors who purchased regeneron shares and suffered substantial losses to submit your losses now.
REGN Ratings Summary
REGN Quant Ranking